Drug, bio-affecting and body treating compositions inventions 04/07

20070093410 - Selective inhibition of proteasomes of tuberculosis and other bacteria: Compositions and methods for inhibiting bacterial proteasomes are provided. Methods of screening antibacterial compounds, methods of treating bacterial infections and disorders associated with bacterial infections, and methods of treating polyglutamine disorders are also provided.... Agent: Banner & Witcoff, Ltd.

20070093411 - Zinc-free and low-zinc insulin preparations having improved stability: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is... Agent: Novo Nordisk, Inc. Patent Department

20070093414 - Hepatitis c virus inhibitors: e

20070093413 - Histone deacetylases, and uses related thereto: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070093412 - Pharmaceutical composition comprising cyclic somatostatin analogues: The present invention describes parenteral pharmaceutical compositions comprising a somatostatin analogue and novel somatostatin analogues.... Agent: Novartis Corporate Intellectual Property

20070093415 - Amyloid specific peptides and uses thereof: Phage peptide display technology was used to identify peptides that bind specifically to the amyloid form of the Aβ1-40 peptide. Peptides with similar structural features and bind to the amyloid form of Aβ1-40 but not to monomeric Aβ1-40, are provided. Such peptides are useful as carrier molecules to deliver therapeutic... Agent: Buchanan, Ingersoll & Rooney LLP

20070093421 - Bio-security system: A method for preventing contamination of a teat during administration of a sealant comprises the steps of introducing/delivering a sterilising agent into the teat and subsequently delivering the sealant into the teat. A sealant injector 1, has a nozzle 3, with a removable protective cap 2. A sterilising agent 4... Agent: Jacobson Holman PLLC

20070093422 - Drug comprising synthetic peptide analogs for the treatment of cancer: The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of... Agent: Ladas & Parry

20070093416 - Human beta-defensin secretion promoter: The present invention provides a human β-defensin secretion promoter that can be used in various forms, such as external preparation, internal preparation, food, etc., and promotes human β-defensin secretion. An organic acid has an effect of promoting the secretion of human β-defensin, particularly human β-defensin-2, and therefore the organic acid... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070093418 - Methods of treatment using specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Marshall, Gerstein & Borun LLP

20070093419 - Methods of treatment using specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Marshall, Gerstein & Borun LLP

20070093417 - Novel glp-1 analogues linked to albumin-like agents: Novel GLP-1 agonists which are protracted by coupling to a protraction protein.... Agent: Novo Nordisk, Inc. Patent Department

20070093420 - Therapy procedure for drug delivery for trigeminal pain: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.... Agent: Morrison & Foerster LLP

20070093423 - Process for production of bivalirudin: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably... Agent: Kenyon & Kenyon LLP

20070093424 - Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases: Small molecule polycationic agents are used to modulate or interrupt biological processes by binding to oligosaccharide-based biomolecules. Compounds that inhibit nitric oxide, TNFα or other immunomodulators are provided and are useful for treating immunological disease and disease of an infectious disorder.... Agent: Connolly Bove Lodge & Hutz LLP

20070093426 - Histone h2a peptide derivatives and analogs and methods of use thereof: Peptides derived from a segment of human histone H2A, the segment corresponding to amino acid residues 36-44 of human histone H2A, are capable of reducing or ameliorating the extent of injury induced by noxious stimuli when administered to animals. Pharmaceutical compositions and methods of using these peptides are also disclosed.... Agent: Winston & Strawn LLP Patent Department

20070093427 - Membrane-permeable nfat inhibitory peptide: The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibition of effectiveness is short and there are no side effects... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070093425 - Vitamin c derivatives with peptide, preparation method thereof and composition comprising the same: Disclosed are vitamin C derivatives linked with a peptide or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a composition comprising the same.... Agent: Medlen & Carroll, LLP

20070093428 - Iap bir domain binding compounds: s

20070093429 - Iap bir domain binding compounds:

20070093431 - Combination of organic compounds: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof and at least one antidiabetic agent.... Agent: Novartis Corporate Intellectual Property

20070093430 - Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070093432 - Camptothecin derivatives as chemoradiosensitizing agents: Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group... Agent: Foley & Lardner LLP

20070093433 - Aminoglycoside antibiotics for use as vap-1/ssao inhibitors: The present invention concerns the use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070093441 - Antigen arrays for treatment of allergic eosinophilic diseases: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070093444 - Chromatin peptides blocking human hif-1alpha gene and modulating the downstream related genes: Chromatin peptide drug molecules, which can block human cell hypoxia responsive pathway, are DNA affinity structural domain of related transcription genes or their imitating molecules or derivatives, containing 5-100 amino acid residues which can specifically bind firmly to HIF-1α gene self promoter or its downstream regulated more than 40 gene... Agent: Frank S. Digiglio Scully, Scott, Murphy & Presser, P.C.

20070093436 - Drop1, a novel marker for carcinogenesis: Described is a novel marker protein associated with epithelial tumors, e.g., ovarian, mammary, stomach, kidney, thyroid and lung carcinomas, Dropl, a dystrophin-related protein as well as a nucleic acid molecule encoding Dropl. Furthermore, various diagnostic and therapeutic uses based on the finding that the expression of Dropl is downregulated in... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070093440 - Medical treatment: An RNAi agent targets a component of a human Notch signalling pathway other than presenilin1 or presenilin2 by RNA interference to reduce expression of said component.... Agent: Frommer Lawrence & Haug

20070093443 - Modified proteases that inhibit complement activation: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be... Agent: Stephanie Seidman Fish & Richardson P.C.

20070093435 - Modulation of cell phenotype by inhibitory rna: We describe a method to inhibit cell division of hyperproliferative cells, typically cancer cells, by introducing inhibitory RNA (RNAi) into said cells to ablate mRNAs that encode polypeptides involved in cellular processes and including RNAi molecules and vectors including transcription cassettes encoding said RNAi molecules. By application of said RNAi... Agent: Klarquist Sparkman, LLP

20070093442 - Modulation of mesenchymal and metastatic cell growth: The present invention relates to compositions and methods for the modulation of metastatic and mesenchymal cell growth and mobility via the regulation of the formation of Twist/Twist homodimers and Twist/E heterodimers. The present invention also relates to methods for screening agents and compound libraries for molecules that function to modulate... Agent: Kevin Farrell Pierce Atwood

20070093434 - Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus: Methods of reducing food intake and glucose production in a mammal, or restoring hepatic autoregulation are provided. The methods involve increasing long-chain fatty acyl-Co-A (LC-CoA) levels in the hypothalamus, or stimulating efferent fibers in the hepatic branch of the vagus nerve. Also provided are methods of increasing food intake and... Agent: Myers Bigel Sibley & Sajovec

20070093437 - Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating XIAP gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of XIAP gene expression and/or activity by... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070093445 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070093439 - Short immunomodulatory oligonucleotides: The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred... Agent: Joseph C. Zucchero Keown & Associates

20070093438 - Use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases: The present invention relates to the significant functional role of several C. elegans genes and of their corresponding gene products in spindle formation or microtubule function during cell division that could be identified by means of RNA-mediated interference (RNAi) and to the identification and isolation of functional orthologs of said... Agent: Connolly Bove Lodge & Hutz, LLP

20070093446 - Orally bioavailable compounds and methods for inhibiting platelet aggregation: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound,... Agent: Howery LLP

20070093448 - Complexes that consist of vitamin d compounds or analogs thereof with a 5z,7e,10(19)-triene system and methylated derivatives of beta-cyclodextrin: The invention relates to complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of β-cyclodextrin, in particular a complex that consists of (thiazol-2-yl)-26,27-dinor-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol and heptakis-(2,6-di-O-methyl)-β-cyclodextrin (DIMEB).... Agent: Millen, White, Zelano & Branigan, P.C.

20070093451 - Compositions of estrogen-cyclodextrin complexes: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since... Agent: Millen, White, Zelano & Branigan, P.C.

20070093447 - Method for crosslinking beta-cyclodextrin for cholesterol trapping and regeneration thereof: Disclosed herein is the use of crosslinked beta-cyclodextrin as a trap for removing cholesterol. The crosslinked beta-cyclodextrin is prepared by crosslinking beta-cyclodextrin in the presence of a crosslinking agent. Treatment with the crosslinked beta-cyclodextrin results in cholesterol-depleted foods. After application to foods, the crosslinked beta-cyclodextrin which traps cholesterol therein can... Agent: Needle & Rosenberg, P.C.

20070093449 - Novel iv formulation of tipifarnib: This invention concerns novel formulations of tipifarnib, which is suitable for intravenous (IV) administration. The invention further concerns the use of such formulation and processes for preparing such formulations and methods of treating by administering said formulations.... Agent: Philip S. Johnson Johnson & Johnson

20070093450 - Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction: The present invention relates to the use of a combination of a PDE5-inhibitor and testosterone for the preparation of a medicament for the treatment of Female Sexual Dysfunction.... Agent: Trask Britt

20070093452 - Use of bivalent or polyvalent trisaccharides as fusion-inhibitors in all hiv types, subtypes, groups, strains, and circulating recombinant forms: This invention relates to compositions containing bivalent or polyvalent trisaccharides, specifically but not exclusively, melezitose and raffinose, and to their use in the treatment/prevention/cure of HIV and AIDS. In particular, such compositions can be used to competitively inhibit formation of the viral fusion complex. This invention also relates to compositions... Agent: Mercedes T. Farquharson

20070093453 - Sulfonamide-substituted chalcone derivatives and their use to treat diseases: i

20070093454 - Pyrimidines and pyrazines useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20070093455 - 10-substituted tetracyclines and methods of use thereof: 10-Substituted tetracycline compounds are described.... Agent: Lahive & Cockfield, LLP

20070093456 - Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis: The present invention is directed to novel derivatives of gambogic acid and analogs thereof. The present invention also relates to the discovery that novel derivatives of gambogic acid are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070093457 - Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid: A composition is provided which comprises an effective amount of curcumin and an effective amount of at least one NSAID for the treatment of cancer and inflammatory diseases and disorders. Also provided are methods of treatment of such diseases and disorders.... Agent: Nath & Associates

20070093458 - Preparation of paricalcitol and crystalline forms thereof: The present invention is directed to a novel process for preparing Paricalcitol wherein Paricalcitol, dissolved in a solvent, is precipitated from a concentrated or seeded solution. The present invention also provides crystalline forms of paricalcitol and processes for their preparations.... Agent: Kenyon & Kenyon LLP

20070093459 - Use of vitamin ds or vitamin d analogs to treat cardiovascular disease: Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin... Agent: Robert Deberardine Abbott Laboratories

20070093460 - Methods of using selective 11beta-hsd inhibitors to treat gluocorticoid associated states: Methods for treating glucocorticoid associated states using selective 11β-HSD1-dehydrogenase, 11β-HSD1-reductase and 11β-HSD2 dehydrogenase modulating compounds are described.... Agent: Lahive & Cockfield, LLP

20070093461 - Effect of loteprednol etabonate on vascular dysfunction: This invention relates to the effect of Loteprednol etabonate on vascular dysfunction in the back of the eye. More specifically, this invention relates to methods of modifying a pathogenic angiogenesis in the back of an eye of a patient, the method comprising administering to a patient in need thereof a... Agent: Bausch & Lomb Incorporated

20070093462 - Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients: Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of... Agent: Needle & Rosenberg, P.C.

20070093463 - Radiation enhancement agent for x-ray radiation therapy and boron neutron-capture therapy: Low toxicity halogenated carborane-containing tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention also includes methods of tumor imaging and/or diagnosis... Agent: Brookhaven Science Associates/ Brookhaven National Laboratory

20070093464 - Beta-lactamase resistant cephalosporin ester compounds and salts of thereof: w

20070093465 - Cephem compound: The present invention is concerned with a novel cephem compound, with a process for the production of this compound, which process may contain or consist of fermentative steps, chemical steps, and/or biotransformation steps. A cephem compound according to the present invention characterised by formula (I) or a salt or ester... Agent: Nixon & Vanderhye, PC

20070093466 - Neurotherapeutic treatment for sexual dysfunction: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of β-lactams, penicillin-binding protein, carboxypeptidase,. Such compounds, including particularly β-lactam ring-containing compounds, can be... Agent: Barnes & Thornburg LLP

20070093468 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitade) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe). Co-administration of the MTP inhibitor with the CAI produces a therapeutic... Agent: Goodwin Procter LLP Patent Administrator

20070093469 - Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments: The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070093467 - Piperidine derivatives and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1... Agent: Townsend And Townsend And Crew, LLP

20070093470 - Lxr modulators: m

20070093471 - Compositions and methods for the administration clozapine formulations which modulate body weight: Embodiments of the invention describe compositions and methods for the administration of fast disintegrating atypical antipsychotics which reduce weight in patients previously taking conventional formulation of atypical antipsychotics. In a preferred embodiment said fast dissolving atypical antipsychotic is FAZACLO.... Agent: Knobbe Martens Olson & Bear LLP

20070093472 - 1-[(4-ethynylphenyl)]-2-[(phenyl)]-pyrrolidine-1,2-dicarboxamide derivatives as inhibitors of coagulation factors xa and viia for the treatment of thromboses: Novel compounds of the formula (I), in which R, R1, R2 and R3 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20070093473 - 7-heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents: with the proviso that when Ar1 is a pyridyl group, and Z is —CH2X— where X is attached to the Ar1 group, X is selected from —CH(OR5)—, —NR5— and —CH2— wherein the —CH2— group may be optionally substituted by one or more C1-6alkyl groups. The compounds of formula (I) are... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070093474 - Methods of modulating neurotrophin-mediated activity: Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.... Agent: Lahive & Cockfield, LLP

20070093475 - Short-acting benzodiazepines: The present invention provides a compound of formula (I): wherein all variables are as defined herein, pharmaceutical formulations containing the same, processes for preparing the same and their use therapy.... Agent: Edwards & Angell, LLP

20070093477 - Alpha2c adrenoreceptor agonists: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070093476 - Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them: The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may... Agent: Milagros A Cepeda Reddy's Laboratories Inc

20070093479 - Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them: e

20070093478 - Novel mycobacterial inhibitors: is equal to 0 or 1 and R7 is hydrogen or Ar. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the... Agent: Philip S. Johnson Johnson & Johnson

20070093480 - Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors:

20070093481 - Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containingthem: The present invention relates to benzopyran derivatives substituted with a thioxobenzoxazole derivative, or pharmaceutically acceptable salts thereof, processes for preparing the same and a pharmaceutical composition containing the above as an effective ingredient Benzopyran derivatives substituted with thioxobenzoxazole derivatives, represented in <Formula 1>, have the function of protecting heart from... Agent: Lucas & Mercanti, LLP

20070093482 - Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors: The invention is also directed to a method for effecting the prophylaxis and therapy of degenerative joint diseases such as osteoarthroses, spondyloses, cartilage loss following joint trauma or a relatively long period of joint immobilization following meniscus or patella injuries or ligament ruptures, diseases of the connective tissue such as... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070093484 - 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators: The present invention relates to 3-substituted-5,6-diarylpyrazine-2-carboxamide and -2-sulfonamide compounds and their compositions, processes for their preparation, and their use in the treatment of obesity and psychiatric and neurological disorders.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070093483 - Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo): There is disclosed the use of a compound of formula (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070093486 - Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof: A process for preparing (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, pharmaceutically acceptable salts and solvates thereof such as the (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride salt via enzyme-catalyzed dynamic kinetic resolutions is provided.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070093487 - Novel polycyclic compounds which modulate ppargamma type receptors and cosmetic/pharmaceutical compositions comprised thereof: p

20070093485 - Substituted n-phenyl sulfonamide bradykinin antagonists: Disclosed are certain substituted N-phenylsulfonamide derivatives and related compounds. These compounds are useful as bradykinin antagonists to relieve adverse symptoms in mammals mediated, at least in part, by bradykinin including pain, inflammation, bronchoconstriction, cerebral edema, etc.... Agent: Foley & Lardner LLP

20070093488 - Novel benzothiazoles and the use thereof as medicaments: The invention especially relates to novel chemical compounds, especially novel benzothiazole derivatives, to compositions containing said compounds, and to the use thereof as medicaments.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070093489 - Phthalazinone derivatives: e

20070093490 - Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments: The invention relates to novel inhibitors of kinases, methods for preparing such inhibitors, intermediates for the preparation of such inhibitors and uses of such inhibitors.... Agent: Millen, White, Zelano & Branigan, P.C.

20070093494 - Novel compounds and their use related to compositions for treating disease: Novel compounds and their uses are disclosed herein.... Agent: Allergan, Inc. (t2-7h)

20070093491 - Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases: The invention provides novel condensed N-pyrazinyl-sulphonamides of formula (I) and their use in the treatment of chemokine mediated diseases.... Agent: Fish & Richardson P.C.

20070093492 - Pyrrolidine derivatives: Pyrrolidine compounds described herein and methods for using them to inhibit dipeptidyl peptidase IV or treat Type II diabetes.... Agent: Fish & Richardson PC

20070093493 - Treatment of benign prostatic hypertrophy and lower urinary tract symptoms: A method of treating symptoms of benign prostatic hypertrophy and a method of treating lower urinary tract symptoms, are disclosed. The method includes administering to a mammal about 1 to about 20 milligrams of an agent that inhibits cyclic guanosine 3,5-monophosphate specific phosphodiesterase type 5.... Agent: Marshall, Gerstein & Borun LLP

20070093496 - Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors: Hydroxy-substituted pyridopyrrolopyrazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I): (I) wherein a, b, A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and... Agent: Merck And Co., Inc

20070093495 - Methods for treatment of parkinson's disease: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070093497 - Methotrexate compliance packaging: The present invention provides a compliance system that contains at least one dispenser including at least one individual dose of an anti-folate therapeutic and at least one individual dose of a folic acid analog, each individual dose of anti-folate therapeutic and folic acid analog positioned in one or more individual... Agent: Townsend And Townsend And Crew, LLP

20070093498 - Thieno-pyrimidine compounds having fungicidal activity: The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.... Agent: Dow Agrosciences LLC

20070093499 - Use of dasatinib for the treatment of bone metastasis: e

20070093500 - Substituted isoindole-1,3-diones: and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods... Agent: Philip S. Johnson Johnson & Johnson

20070093502 - 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication: d

20070093501 - Urea derivative, process for producing the same, and use:

20070093503 - Methods and kit for treating parkinson's disease: The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.... Agent: Harness, Dickey, & Pierce, P.l.c

20070093504 - Salts of modulators of ppar and methods of treating metabolic disorders: Salt forms of potent modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.... Agent: International Patent Group Attn: Ms Lavern Hall

20070093505 - 2,3-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators: The present invention relates to 2,3-substituted-4,5-diarylpyrazine compounds and their compositions, processes for their preparation, and their use in the treatment of obesity and psychiatric and neurological disorders.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070093506 - Inhibitors of tyrosine kinases: wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy... Agent: Novartis Corporate Intellectual Property

20070093507 - Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives: The present invention relates to a fixed combination of a benzo[g]quinoline derivative and a prostaglandin derivative, and their use as pharmaceuticals, especially for treating glaucoma.... Agent: Novartis Corporate Intellectual Property

20070093508 - Non-basic melanin concentrating hormone receptor-1 antagonists: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for... Agent: Louis J. Wille Bristol-myers Squibb Company

20070093509 - Non-basic melanin concentrating hormone receptor-1 antagonists: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for... Agent: Louis J. Wille Bristol-myers Squibb Company

20070093510 - Phosphodiesterase 4 inhibitors: e

20070093511 - Anhydrous crystal form of valaciclovir hydrochloride: The invention relates to anhydrous crystalline valaciclovir hydrochloride, pharmaceutical compositions containing the same, its use in medical therapy and processes for preparing the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070093512 - Heterocyclic compounds: Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070093513 - Agent for repairing corneal perception: The present invention provides a novel pharmaceutical agent for recovering corneal sensitivity after corneal surgery and improving symptoms of dry eye. This pharmaceutical agent is useful for improving decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as post-cataract operation, post-LASIK operation, post-PRK operation, postkeratoplasty operation, neuroparalytic keratopathy,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070093514 - Therapeutic agent for keratoconjunctival disorder: An object of the present invention is to discover a new medicinal use of 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]p henylmethyl]thiazolidine-2,4-dione and N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine. Both of the compounds exert an excellent improving effect on corneal disorder models and is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis,... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070093515 - Phosphodiesterase 10 inhibitors: Provided are certain quinazolines that are PDE10 inhibitors, pharmaceutical compositions, containing the same and processes for preparing the same. Also provided are methods of treating diseases treatable by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like, by administering those certain quinazolines.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070093516 - Methods and formulations for modulating lyn kinase activity and treating related disorders: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder... Agent: Cozen O'connor, P.C.

20070093517 - Local anesthetic compositions: The treatment of pain and related use by topical administration of an N-substituted-14-hydroxydihydronormorphine to a subject in need thereof. In some embodiments, the N-substituted-14-hydroxydihydronormorphine is nalbuphine.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070093519 - Anti-emetic uses of cannabinoid analogs: The present invention relates to non-psychoactive cannabinol analogs of tetrahydrocannabinol, (3R,4R)-Δ8—THC-11-oic acids, for treating and preventing nausea and relieving symptoms thereof.... Agent: Foley And Lardner LLP Suite 500

20070093518 - Pharmaceutical compositions for the treatment of organophosphate poisoning: A pharmaceutical composition comprising (i) a carbamate; (ii) a first anticholinergic; (iii) a second anticholinergic; and (iv) a pyridinium salt. The pharmaceutical composition is suitable for the treatment of organophosphate poisoning, including nerve agent and pesticide poisoning. The pharmaceutical composition provides an effective therapy against the lethal effects of nerve... Agent: Nixon & Vanderhye, PC

20070093520 - Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject: A method of treatment of diarrhea-predominant IBS in a subject, comprising administering to a subject in need of treatment a therapeutically effective amount of a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof; and providing information that indicates that constipation, abdominal pain, upper respiratory tract infection and/or nausea may... Agent: Mayer, Brown, Rowe & Maw LLP

20070093521 - Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives: wherein X, A, B, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070093522 - Peptidomimetic ligands for cellular receptors and ion channels: One aspect of the present invention relates to novel peptidomometic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands—agonists or antagonists—for various cellular receptors, e.g., G-protein-coupled receptors and opioid receptors, and various cellular ion channels, e.g., sodium and calcium. In... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070093523 - Tetrahydroisoquinoline lxr modulators: e

20070093524 - 5-lipoxygenase modulators: The present invention provides the use of Liver X Receptor (LXR) modulators that have been identified to downregulate 5-lipoxygenase gene expression in order to treat various diseases and disorders that involve the function of the 5-LO protein in intracellular signaling (or other cellular processes) or the function of protein products... Agent: Wilmerhale/wyeth

20070093525 - Triamide-substituted heterobicyclic compounds: e

20070093526 - 4-amino-piperidine derivatives as monoamine uptake inhibitors: The present invention provides compounds of formula (I) where n, R1, R2, R3, R4, R5 and Heteroaryl are defined herein. The compounds are inhibitors of the uptake of one or more monoamines selected from serotonin, norepinephrine and dopamine and, as such, may be useful in the treatment of disorders of... Agent: Eli Lilly & Company

20070093527 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a HMG-CoA reductase inhibitor (for example simvastatin or atorvastatin). Co-administration of the MTP inhibitor with the HMG-CoA reductase inhibitor... Agent: Goodwin Procter LLP Patent Administrator

20070093528 - Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them: The present invention provides pyridine derivatives useful as intermediates of drugs and agricultural chemicals, electrophotographic receptors, dyes and so on. More specifically, the invention relates to novel pyridyltetrahydropyridines and novel pyridylpiperidines, and further to a method of manufacturing pyridine derivatives through reaction between bipyridine derivatives and benzyl halide or benzyloxycarbonyl... Agent: Sughrue Mion, PLLC

20070093529 - Diacylhydrazine derivatives: The present invention relates to diacylhydrazine derivatives of formula I, the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.... Agent: Millen, White, Zelano & Branigan, P.C.

20070093531 - Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them: The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to... Agent: Fulbright & Jaworski L.L.P.

20070093530 - Substituted indolealkanoic acids: Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070093532 - Benzimidazole carboxamides as raf kinase inhibitors: The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering... Agent: Heller Ehrman LLP

20070093533 - Crystalline s-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same: This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.... Agent: Sughrue Mion, PLLC

20070093534 - Modulation of pathogenicity: i

20070093535 - Vinyl phenyl derivatives as glk activators: The invention related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein A, R1, R2, R3, n and m are as described in the specification, useful in the treatment of a disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention... Agent: Morgan Lewis & Bockius LLP

20070093536 - Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto: The present invention is intended to elucidate a molecular target of an antidiabetic such as a thiazolidine derivative. The present invention provides a screening method for an antidiabetic, comprising the steps of: bringing a candidate substance to be screened into contact with a protein represented by the following (a) or... Agent: Birch Stewart Kolasch & Birch

20070093537 - Thiazolyl-based compounds useful as kinase inhibitors: useful for treating p38 kinase-associated conditions, wherein ring A is phenyl or pyridyl, and X, Y, B, R2, R3, Z1 m and n are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and... Agent: Louis J. Wille Bristol-myers Squibb Company

20070093538 - Preparation for the fungicidal and algicidal finish of alkaline coating compositions: The invention relates to a preservative comprising at least one isothiazolone, at least one quaternary ammonium compound, and at least one stabilizer selected from the group of sulphite salts, hydrogen sulphite salts, sulphite-releasing compounds and hydrogen-sulphite-releasing compounds, the presence of algicidal triazine being ruled out. The preservative inhibits the growth... Agent: Linda K. Russell

20070093539 - N-hydroxy-4-(3-pheyl-5-methyl-isoxazole-4-yl)-benzenesulfonate solvates: [solvate] represents water, C1-C4 alcohol, C1-C4 alkylester of C1-C3 carboxylic acid or dioxane, and the mixture of solvated (wherein n=1) and solvat-free forms (wherein n=0). Furthermore, the invention relates their process for production and use for the treatment of osteoarthritis and rheumatoid arthritis and surgical and primary dysmenorrheal pains, based... Agent: The Firm Of Karl F Ross

20070093540 - process for the preparation of angiotensin ii antagonistic compounds: A process for the preparation of angiotensin II antagonists and novel intermediates useful for the synthesis thereof.... Agent: Griffin & Szipl, PC

20070093541 - Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors: The invention relates to a method of treatment of dementia and/or regression of cognitive function, comprising co-administration of effective amounts of an Angiotensin II antagonist and an Angiotensin I Converting Enzyme inhibitor, pharmaceutical compositions containing an Angiotensin II antagonist together with an ACE inhibitor and the use of an Angiotensin... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070093542 - Process for the preparation of valsartan and intermediates thereof: Provided are process for the preparation of valsartan and the precursors thereof.... Agent: Kenyon & Kenyon LLP

20070093543 - Fungicidal mixtures based on carbamate derivatives and insecticides: The present invention relates to mixtures comprising as active components a) carbamate derivatives of the formula (I) in which the substituents and the index have the following meaning: T is CH or N n is 0, 1 or 2 R is halogen, C1-C4-alkyl or C1-C4-haloalkyl, it being possible for the... Agent: Hutchison Law Group PLLC

20070093544 - Benzamidazoles, compositions containing such compounds and methods of use: The present invention relates to substituted benzimidazoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.... Agent: Merck And Co., Inc

20070093545 - 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof: System for selecting a colour shade comprising a very small number of colour display cards with mixed shades of two or more colours. The system comprises means for selecting one shade among mixed shades, means for presenting the selected mixed shade as well as means for specifying the selected mixed... Agent: Arena Pharmaceuticals, Inc.

20070093546 - Use of rotigotine for the treatment of depression: The present invention relates to the use of rotigotine [(−)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol] and its prodrugs and pharmaceutically acceptable salts for producing a pharmaceutical agent for treating depression.... Agent: Harness, Dickey, & Pierce, P.l.c

20070093547 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070093548 - Use of progesterone receptor modulators:

20070093549 - Methods for preparation of ladostigil tartrate crystalline form a1: Provided are processes for preparing crystalline ladostigil tartrate form A1.... Agent: Kenyon & Kenyon LLP

20070093550 - Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as aids: A method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as acquired immunodeficiency syndrome (AIDS) includes a glycol derivative. More specifically, the glycol derivative includes diethylene glycol dibenzoate.... Agent: Dinesh Agarwal, P.C.

20070093551 - Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites: A composition and method for producing a beneficial effect on a subject's nerve associated with at least one of a cosmetic condition, a dermatological indication and a dental indication and another condition. The composition comprises a hydroxy-oligocarboxylic ester and is formulated for topical administration of the product to a subject... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070093552 - Early insulin secretion stimulator: The invention provides an early insulin secretion stimulator consisting of corosolic acid, etc. The early insulin secretion stimulator of the invention is capable of rapidly inducing secretion of insulin immediately after meals without inducing secretion of excess insulin in the absence of blood glucose increase.... Agent: Morgan Lewis & Bockius LLP

20070093553 - Hmb compositions and uses thereof: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20070093554 - Agent for improving feeling of cold: It is desirable to provide a medicament or nutritional food to improve feeling of cold and to create fulfilling life for people who are suffering from feeling of cold. Specifically, one object of the present invention is to provide an, agent, a food and drink, or a food additive which... Agent: Darby & Darby P.C.

20070093555 - Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same: Topical pain relief compositions of N,2,3-trimethyl-2-isopropylbutamide and methods for using the same are provided. The subject compositions include a pain relieving effective amount of N,2,3-trimethyl-2-isopropylbutamide in a topical formulation, e.g., a patch, gel, cream or foam. Also provided are methods of using the subject compositions in pain relief applications.... Agent: Bozicevic, Field & Francis LLP

20070093556 - Toremifene crystallization method: The invention relates to a method for isolating toremifene from a mixture of toremifene and its corresponding E isomer. The method comprises contacting the isomer mixture with a first solvent comprising methanol, allowing toremifene to crystallize in said first solvent, allowing the crystallized product of the previous step to crystallize... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070093557 - Sertraline hydrochloride form ii and methods for the preparation thereof: The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized... Agent: Steven J. Lee Kenyon & Kenyon

20070087958 - Compounds and compositions for delivering active agents: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.... Agent: Darby & Darby P.C.

20070087957 - Methods and compositions for oral administration of proteins: This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.... Agent: Pearl Cohen Zedek Latzer, LLP

20070087959 - Method of inducing biomineralization method of inducing bone regeneration and methods related thereof: A method of inducing biomineralization in a tissue, which method comprises administering to the tissue a source of Phosphophoryn (PP) in an amount sufficient to induce biomineralization; a method of treating tooth sensitivity or injured pulp tissue; a method of inducing differentiation of a cell into an osteogenic cell or... Agent: Leydig Voit & Mayer, Ltd

20070087961 - Conjugates of hydroxyalkyl starch and erythropoietin: Conjugates of hydroxyethyl starch and erythropoietin are provided. The conjugates comprise a linking compound that is covalently linked to erythropoietin and covalently linked to hydroxyethyl starch. Methods of producing the conjugates, and their use, also are provided.... Agent: Fish & Richardson P.C.

20070087960 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070087962 - Pharmaceutical compositions comprising cyclosporins: A liquid comprising a therapeutically effective concentration of a cyclosporin and a vitamin E tocopherol polyethylene glycol succinate, wherein said liquid is an emulsion. is disclosed herein. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.... Agent: Brent A. Johnson Allergan, Inc.

20070087963 - Synthesis of cyclosporin analogs: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis... Agent: Fish & Richardson P.C.

20070087967 - Methods and compositions for inhibiting angiogenesis: The present invention provides a method of inhibiting angiogenesis within a tissue by providing exogenous PEDF to cells associated with the tissue. The presence of exogenous PEDF inhibits angiogenesis within the tissue, in part by interfering with the ability of vascular endothelia to expand within the tissue. The invention also... Agent: Morgan, Lewis & Bockius LLP

20070087968 - Methods to treat t-cell disorders using tisf: T4 Immune Stimulating Factor (TISF) selectively induces aberrant T-cells to initiate apoptosis. TISF and peptides that are related to TISF (TISF peptides) are therefore useful for the treatment of disorders characterized by aberrant production, development, or activity of T-cells or other cells of hematopoietic origin. This invention relates to methods... Agent: Morrison & Foerster LLP

20070087964 - Novel compositions and methods for modulating the acid-sensing ion channel (asic): Novel compositions for modulating acid-sensing ion channels (ASIC) function comprising ASICα, ASICβ, and BNC1 and derivatives thereof; methods for modulating ASIC function and methods for treating cognitive disorders and for memory enhancement using the novel compositions of the invention; and a method for increasing synaptic plasticity are described.... Agent: Mckee, Voorhees & Sease, P.L.C

20070087966 - Prolactin and chronic and acute pain disorders: The embodiments disclosed herein provide methods for inhibiting, reducing and/or treating pain in a subject by administering to a subject in need thereof a pharmaceutical formulation that includes a pharmacologically active compound that is adapted to disrupt PRL signaling in pain neurons. In certain embodiments, the compound is a PRL-R... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20070087965 - Treatment of psoriasis through down-regulation of the egf-receptor with topically applied egf: From unrelated but similar fields it is deduced that certain forms of psoriasis can be effectively treated through topical application of EGF-containing formulations. This patent application summarizes the theoretical basis for this finding and requests protection for the idea, while clinical evaluation is in preparation.... Agent: Bell, Boyd, & Lloyd LLP

20070087970 - Use of c-reactive protein to treat immune complex-mediated renal disease: The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus.... Agent: Henry D. Coleman

20070087969 - Wound healing and treatment of fibrosis: Compositions for use in the treatment of wounds and fibrosis comprising a therapeutically effective amount of a compound that modulates actin assembly and organization intracellularly and/or extracellularly and a pharmaceutically acceptable vehicle; such a compound promotes the rate of wound healing and also prevents or reduces fibrosis. A preferred compound... Agent: Nixon & Vanderhye, PC

20070087971 - Peptides, derivatives and analogs thereof, and methods of using same: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment... Agent: Pepper Hamilton LLP

20070087972 - Prion-specific peptoid reagents: The invention relates to peptoid reagents that interact preferentially with a pathogenic form of a conformational disease protein as compared to a nonpathogenic form of the conformational disease protein where the peptoid reagent comprises an amino-terminal region, a carboxy-terminal region, and at least one peptoid region between the amino-terminal region... Agent: Novartis Vaccines And Diagnostics Inc.

20070087973 - Processes and intermediates: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.... Agent: Miller Canfield Paddock And Stone PLC

20070087974 - Treatment or prevention of respiratory viral infections with immunomodulator compounds: An immunomodulatory compound is administered to a patient having, or at risk of a respiratory viral infection.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070087975 - Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients: Is described a method of treating left ventricular hypertrophy comprising administering an effective amount of propionyl L-carnitine, or a pharmaceutical salt thereof, to ESRD or dialysed patients in need of such treatment.... Agent: Nixon & Vanderhye, PC

20070087978 - Method of controlling animal pests: A method of treating plant and animal systems and inanimate surfaces for the purposes of controlling plant pests, introducing pesticides and nutrients into plants, mitigating frost damage to plants, increasing crop yields, controlling certain plant diseases, controlling arthropod, bacterial, fungal, mycoplasma, rickettsia, and viral pests of animals and humans, and... Agent: Craig Gregersen Law Offices Of Craig Gregersen

20070087977 - Methods and compositions for treating pain: Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular,... Agent: Wilson Sonsini Goodrich & Rosati

20070087976 - Topiramate and pharmaceutical formulations thereof: As demonstrated herein, topiramate can be rendered substantially non-hygroscopic if present in a particularly pure form and with a small particle size. Accordingly, the present invention relates to a highly pure form of topiramate, having a particle size of ≦250 μm, and pharmaceutical formulations which contain this active substance.... Agent: Smith Patent Consulting Consulting, LLC

20070087979 - Sulfatides for treatment of autoimmune disorders: Disclosed herein are methods for the treatment of autoimmune or immune related diseases or disorders. Also disclosed are methods for treating such autoimmune or immune related diseases or disorders with the administration of sulfatides. Also disclosed herein are methods of treating autoimmune or immune related diseases or disorders by administering... Agent: Knobbe Martens Olson & Bear LLP

20070087980 - azithromycin-containing aqueous pharmaceutical composition and a method for the preparation of the same: The invention provides an azithromycin-containing aqueous pharmaceutical composition, which comprises at least one member selected from the group consisting of azithromycin, its anhydride, its hydrate, and pharmaceutically acceptable salts thereof, and at least one member selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, amino acid, ethylenediaminetetraacetic acid, and pharmaceutically... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070087981 - Water soluble and palatable complexes: The products and methods of the present invention provide a means for increasing the solubility and bioavailability of active agents. More particularly the invention provides compositions containing active agents as water-soluble complexes with glycyrrhizin, and methods of preparing such complexes. The invention further provides methods for the preparation of highly... Agent: Lucas & Mercanti, LLP

20070087992 - Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof: A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous... Agent: Ip Group Of Dla Piper US LLP

20070087990 - Cc chemokine receptor 5 dna, new animal models and therapeutic agents for hiv infection: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step... Agent: Klarquist Sparkman, LLP

20070087986 - Compositions and methods for enhancing immunity by chemoattractant adjuvants: The invention is directed to methods and compositions for enhancing immunity, including mucosal immunity. The compositions include an antigen or immunogen, a ligand for a Toll-like receptor and at least one chemoattractant.... Agent: Magdalena O. Cilella Brinks Hofer Gilson & Lione

20070087988 - Hematopoietic progenitor kinase 1 for modulation of an immune response: Methods of regulating hematopoietic progenitor kinase 1 (HPK1) are described as are methods of identifying compounds that can regulate HPK1.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070087984 - Method of identifying agents that inhibit the growth of cancer cells: The present invention is directed to methods of identifying agents useful for inhibiting cancer cells. The agents bind to one of the proteins described herein, or to a gene or mRNA encoding such protein. The invention is also directed to methods for inhibiting cancer cells by administering an agent that... Agent: Law Office Of David Spolter G Singer

20070087989 - Methods of treating ocular conditions: The present invention provides siRNA specific for myocilin and mutant myocilin, and methods of treating ocular conditions and/or diseases.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070087982 - Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences: Applicants have used microarrays, gene expression profiling, and gene silencing methods to identify and provide a plurality of ‘validated’ virus-induced cellular gene sequences (e.g., HMG20B, HRH1, NP and c-YES (src family kinases)) and pathways useful as therapeutic targets for modulation of viral-mediated cellular effects. Particular embodiments provide therapeutic compositions, and... Agent: Klarquist Sparkman, LLP

20070087987 - Modulation of glucagon receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides which have particular in vivo properties, targeted to nucleic acids encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for treatment of diseases... Agent: Elmore Patent Law Group

20070087985 - Mrck-related compositions and methods: This invention provides a composition comprising a pharmaceutically acceptable carrier and a nucleic acid which, when introduced into a cell wherein MRCK is expressed, inhibits the expression of MRCK in the cell. This invention further provides a method for identifying an agent that inhibits MRCK expression in a cell. This... Agent: Cooper & Dunham, LLP

20070087983 - Novel ubp8rp polypeptides and their use in the treatment of psoriasis: The invention encompasses a novel gene encoding a protein of the ubiquitin-proteasome pathway, UBP8rp. The invention also relates the use of UBP8rp polypeptides for screening for modulators, and to the use of said modulators for treating chronic inflammatory diseases such as, e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070087991 - Pluripotential stem cells: We describe a method to manipulate the phenotype of stem cells, preferably pluripotential stem cells including nucleic acids and vectors used in said methods.... Agent: Crowell & Moring LLP Intellectual Property Group

20070087993 - Method for transdifferentiation of body tissues: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases.... Agent: Darby & Darby P.C.

20070087994 - A1 adenosine receptor agonists: Disclosed are novel compounds that are A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, diseases related to release of nonesterified fatty acids, and myocardial infarction.... Agent: Cv Therapeutics, Inc

20070087995 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The... Agent: King & Spalding LLP

20070087996 - Method of extracting fucoidan: A method of extracting fucoidan from a biological material is provided. The method comprises (a) combining a biological material containing fucoidan and a medium to form a mixture; (b) applying ultrasonic waves to the mixture while the mixture is at a temperature of less than about 60 C; (c) extracting... Agent: The Maxham Firm

20070087997 - Methods for producing modified microcrystalline chitosan and uses therefor: Disclosed are methods of producing modified microcrystalline chitosan. Chitosan in aqueous solution is degraded enzymatically, hydrolytically or oxidatively. The chitosan solution is then alkalized with agitation using aqueous hydroxides and/or their salts to attain a pH not lower than 7.0. The precipitated modified microcrystalline chitosan is highly pure and may... Agent: Dykema Gossett PLLC

20070088000 - Beta-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases: Methods of reducing the risk of transmission of a sexually transmitted pathogen by contacting the pathogen or cells susceptible to infection by the pathogen with a β-cyclodextrin are provided. Methods for reducing the risk of transmission of a sexually transmitted pathogen to or from a subject by contacting the pathogen... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070087998 - Imidazole compounds that modulate hsp90 activity: Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070087999 - Pharmaceutical compositions containing cyclodextrins and taxoids: The present invention relates to water-soluble solid pharmaceutical compositions and their solutions in aqueous solvents, said compositions containing a) as an active ingredient a finely dispersed large surface area amorphous preferably lyophilized taxoid such as paclitaxel or docetaxel, their salts or their polymorphic hydrates or solvates such as solvates formed... Agent: Davidson, Davidson & Kappel, LLC

20070088001 - Silinane compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Berlex Biosciences Patent Department

20070088002 - Orally available sphingosine 1-phosphate receptor agonists and antagonists: The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is selected from the... Agent: University Of Virginia Patent Foundation

20070088003 - Asthma associated factors as targets for treating atopic allergies including as